Cathepsin B Protein (Ctsb) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about Cathepsin B Protein, including its structure, normal function in the nervous system, and its role in neurodegenerative diseases.
:: infobox infobox-protein
!Protein Name | Cathepsin B (CTSB)
!Gene | CTSB
!UniProt ID | P07846
!PDB Structure | 1HUC, 2G51, 4P7G
!Molecular Weight | ~26 kDa (heavy chain) + ~8 kDa (light chain)
!Subcellular Localization | Lysosomes, endosomes
!Protein Family | Cysteine cathepsins (papain family)
!
Cathepsin B is a lysosomal cysteine protease with unique features:
Cathepsin B is unique among cathepsins because it has occluding loop that gives it both endopeptidase and exopeptidase (dipeptidyl carboxypeptidase) activity.
Cathepsin B exhibits widespread expression across multiple tissue types:
Cathepsin B has important physiological roles:
Protein Degradation: Major lysosomal protease that degrades proteins, including extracellular matrix components
Antigen Processing: Processes antigens for MHC class II presentation in antigen-presenting cells
Apoptosis Regulation: Can activate or inhibit apoptotic pathways depending on context
Extracellular Remodeling: Under certain conditions, secreted cathepsin B degrades ECM and basement membrane components
Hormone Processing: Activates prohormones in the secretory pathway
Immune Response: Modulates inflammasome activation and cytokine release
Cathepsin B is implicated in AD pathogenesis:
Cathepsin B uses a cysteine protease mechanism:
| Approach | Status | Description |
|---|---|---|
| Cathepsin B Inhibitors | Preclinical | Small molecules (CA-074, E-64) for AD and cancer |
| Targeted Delivery | Research | Brain-penetrant inhibitors using nanoparticle delivery |
| Activity Modulation | Preclinical | Modulate rather than completely inhibit to preserve normal function |
| Gene Therapy | Experimental | AAV-mediated delivery of inhibitory peptides |
Yan S, et al. (2020) "Cathepsin B and Alzheimer's disease." Adv Exp Med Biol 1235:85-104. DOI:10.1007/978-3-030-41679-9_4
Hook G, et al. (2014) "Cathepsin B in neurodegeneration of Alzheimer's disease." Curr Alzheimer Res 11:654-664.
Vidak E, et al. (2019) "Cathepsin B: A potential therapeutic target in neurodegeneration." J Neurochem 150:501-517. DOI:10.1111/jnc.14818
Benes P, et al. (2008) "Cathepsin B: multiple functions in cancer." Neoplasma 55:253-264.
Hook V, et al. (2021) "Cathepsin B: therapeutic target for neurodegenerative diseases." Nat Rev Drug Discov 20:33-48.
The study of Cathepsin B Protein (Ctsb) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Reference 1
[2] Reference 2
[3] Reference 3
[4] Reference 4
[5] Reference 5